treatment with REC-994 400 mg showed promising signals in both MRI-based lesion volume reduction and functional outcome as ...

Showed promising signals of efficacy in MRI-based lesion volume reduction and functional outcomes measured by changes in the modified Rankin scale (mRS) in patients receiving REC-994 400 mg.

Revalesio updates new analyses from phase 2 RESCUE clinical study of RNS60 in patients with acute ischemic stroke: Tacoma, Washington Friday, February 7, 2025, 18:00 Hrs [IST] Rev ...

The following is a summary of “Endovascular Thrombectomy for Extracranial Internal Carotid Artery Occlusions With Large ...

In any case, there was no mortality signal associated with alteplase administered up to 24 hours after a stroke in HOPE.

In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO ...

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison to placebo, treatment with REC-994 400 mg showed promi ...

In patients with high comorbidity burden that receive EVT for MCA medium-vessel occlusion there are worse clinical outcomes.

The modified Rankin Scale (mRS) is a commonly used functional outcome assessment in stroke clinical trials and has become an essential metric for stroke research. However, the mRS is not routinely ...

Background: We investigate whether the NIHSS at 24 hours could serve as an alternative primary outcome measure in acute ischemic stroke trials, and whether combining 90-day modified Rankin Score (mRS) ...

Secondary outcomes were door-to-needle time, neurological deficits (assessed using the National Institutes of Health Stroke Scale [NIHSS ... (measured using the modified Rankin Scale [mRS ...

Functional recovery at 90 days was lower in the balloon-guided catheter group versus the conventional catheter group. 2.